With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers
Bay Area start-up is pursuing therapies targeting biology shared by pediatric and adult cancers
Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make the former a driving force instead of an afterthought.
Incubated by Canaan, Day One Biopharmaceuticals LLC is also funded by Access Biotechnology and Atlas Venture.
On average, companies make investigational cancer therapies available to children